Double maintains 3 strategies that include RCUS - Arcus Biosciences, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| XNCR | 50.97% | $628.44M | -55.20% | 0.00% |
| ACLX | 48.35% | $3.80B | +10.49% | 0.00% |
| IDYA | 48.20% | $1.97B | -43.80% | 0.00% |
| OCUL | 48.01% | $1.76B | +35.67% | 0.00% |
| IMNM | 47.34% | $751.79M | -35.95% | 0.00% |
| APGE | 45.98% | $2.27B | -20.57% | 0.00% |
| SPSC | 45.46% | $5.00B | -34.32% | 0.00% |
| DLX | 45.04% | $731.94M | -26.57% | 7.35% |
| TBCH | 44.87% | $278.42M | -7.19% | 0.00% |
| OC | 44.61% | $12.54B | -16.92% | 1.75% |
| STEP | 44.45% | $4.59B | +29.43% | 1.61% |
| BNT | 44.30% | $12.68B | +37.18% | 0.00% |
| RVMD | 44.29% | $7.08B | -15.77% | 0.00% |
| IMVT | 44.24% | $3.10B | -40.69% | 0.00% |
| SITE | 44.18% | $5.79B | -0.75% | 0.00% |
| LFUS | 44.05% | $5.78B | -13.47% | 1.20% |
| BN | 43.94% | $104.09B | +37.27% | 0.54% |
| BBSI | 43.42% | $1.11B | +29.20% | 0.75% |
| AVNT | 43.40% | $3.13B | -21.91% | 3.13% |
| PNR | 43.35% | $17.62B | +35.15% | 0.90% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -23.57% | $24.61B | +38.65% | 1.07% |
| K | -13.97% | $27.56B | +40.50% | 2.87% |
| VSTA | -10.52% | $324.82M | +33.88% | 0.00% |
| BULL | -8.67% | $6.05B | +11.93% | 0.00% |
| LITB | -7.92% | $24.09M | -72.65% | 0.00% |
| OSCR | -7.37% | $3.66B | -12.95% | 0.00% |
| AQB | -7.19% | $3.00M | -57.88% | 0.00% |
| PCRX | -7.19% | $1.06B | +5.24% | 0.00% |
| TEF | -6.71% | $29.40B | +18.14% | 6.29% |
| AWK | -6.42% | $27.75B | +2.31% | 2.19% |
| WBA | -6.23% | $9.97B | +0.17% | 4.34% |
| HUSA | -5.41% | $23.23M | +4.02% | 0.00% |
| MO | -5.40% | $97.36B | +21.10% | 7.03% |
| ED | -5.11% | $36.24B | +9.11% | 3.33% |
| AGL | -5.08% | $923.11M | -64.55% | 0.00% |
| VSA | -4.81% | $10.37M | +7.96% | 0.00% |
| CME | -3.64% | $99.13B | +45.75% | 1.74% |
| BAH | -3.50% | $13.27B | -32.38% | 1.99% |
| CYD | -3.50% | $924.08M | +167.72% | 3.68% |
| KR | -3.42% | $46.66B | +34.46% | 1.80% |
Current Value
$9.281 Year Return
Current Value
$9.281 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HTO | -0.01% | $1.74B | -12.67% | 3.24% |
| CIG.C | 0.07% | $2.64B | +21.24% | 0.00% |
| NEUE | -0.08% | $60.98M | +33.14% | 0.00% |
| AMT | 0.09% | $102.63B | +4.10% | 3.02% |
| CARV | 0.10% | $9.29M | +17.31% | 0.00% |
| DUK | -0.31% | $91.30B | +11.45% | 3.57% |
| MSEX | -0.48% | $979.70M | -7.98% | 2.40% |
| WTRG | -0.53% | $10.47B | -7.67% | 3.47% |
| CCEC | -0.62% | $1.02B | +3.91% | 2.46% |
| MSIF | -0.68% | $763.81M | +35.16% | 7.65% |
| ARRY | 0.70% | $1.14B | -36.48% | 0.00% |
| HE | -0.79% | $1.82B | +1.34% | 0.00% |
| HIHO | 0.84% | $7.50M | -23.51% | 4.29% |
| UUU | -0.87% | $7.70M | +126.53% | 0.00% |
| KO | -1.04% | $300.74B | +9.69% | 2.85% |
| OXBR | -1.19% | $17.42M | -7.87% | 0.00% |
| AEP | 1.20% | $56.27B | +15.81% | 3.49% |
| PINC | 1.26% | $1.74B | +12.25% | 3.96% |
| CLRB | -1.30% | $13.06M | -93.57% | 0.00% |
| COR | 1.40% | $57.22B | +32.62% | 0.73% |
Yahoo
HAYWARD, Calif., July 10, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer.
Finnhub
Arcus Biosciences, Inc. announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration for the treatment...
Finnhub
By Freddy Sebastian Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company...
Yahoo
HAYWARD, Calif., July 09, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 54,800 shares of the Company’s common stock at an exercise price per share of $8.50, which was the closing price on July 8, 2025, and restrict
Yahoo
Arcus Biosciences, Inc. (NYSE:RCUS) is one of the 12 Small Cap Stocks with High Upside Potential. On June 1, Arcus Biosciences presented the first data for casdatifan plus cabozantinib in oral metastatic kidney cancer, which showed a confirmed response. The trials by Dr. Toni K. Choueiri showed a confirmed overall response rate of 46% in […]
Finnhub
Arcus Biosciences, Inc. added to Russell 3000 Value Index...
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -38.56% | $200.94M | 0.85% |
| VIXM | -37.17% | $22.99M | 0.85% |
| TAIL | -36.43% | $94.90M | 0.59% |
| BTAL | -34.20% | $310.24M | 1.43% |
| IVOL | -27.99% | $341.06M | 1.02% |
| XONE | -18.27% | $629.16M | 0.03% |
| BSMW | -17.06% | $107.58M | 0.18% |
| UTWO | -15.54% | $376.64M | 0.15% |
| IBTG | -15.53% | $1.93B | 0.07% |
| SHYM | -15.44% | $355.87M | 0.35% |
| VGSH | -15.19% | $22.70B | 0.03% |
| ULST | -15.00% | $592.71M | 0.2% |
| IBTH | -14.96% | $1.62B | 0.07% |
| FTSD | -14.89% | $233.24M | 0.25% |
| SCHO | -14.58% | $10.92B | 0.03% |
| TPMN | -14.41% | $30.86M | 0.65% |
| SPTS | -13.91% | $5.78B | 0.03% |
| STOT | -13.50% | $254.22M | 0.45% |
| CTA | -13.41% | $1.07B | 0.76% |
| LDUR | -12.36% | $907.64M | 0.5% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| MMIT | -0.07% | $1.03B | 0.3% |
| BNO | 0.07% | $108.34M | 1% |
| IGOV | 0.08% | $1.25B | 0.35% |
| PWZ | 0.29% | $787.40M | 0.28% |
| ITM | -0.34% | $1.87B | 0.18% |
| IBMP | -0.37% | $554.05M | 0.18% |
| MMIN | 0.43% | $321.61M | 0.3% |
| NUBD | 0.47% | $397.19M | 0.16% |
| SHM | -0.52% | $3.41B | 0.2% |
| TAXF | -0.52% | $478.14M | 0.29% |
| JPST | -0.58% | $32.02B | 0.18% |
| AGGH | 0.62% | $323.85M | 0.29% |
| CGSD | 0.62% | $1.39B | 0.25% |
| USO | 0.64% | $1.03B | 0.6% |
| IBTP | 0.68% | $143.68M | 0.07% |
| CANE | -0.70% | $11.17M | 0.29% |
| IBND | -0.79% | $407.57M | 0.5% |
| USL | 0.85% | $43.14M | 0.85% |
| IBDR | -0.86% | $3.34B | 0.1% |
| DBE | -0.97% | $53.74M | 0.77% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 57.98% | $5.19B | 0.35% |
| GNOM | 53.67% | $45.27M | 0.5% |
| IBB | 53.57% | $5.59B | 0.45% |
| PBE | 52.59% | $233.59M | 0.58% |
| IWC | 50.88% | $846.53M | 0.6% |
| KJUL | 49.96% | $160.44M | 0.79% |
| IWO | 49.93% | $11.96B | 0.24% |
| IWM | 49.76% | $67.25B | 0.19% |
| VTWO | 49.72% | $12.69B | 0.07% |
| KJAN | 49.50% | $283.13M | 0.79% |
| SCHA | 49.22% | $17.85B | 0.04% |
| XPH | 48.97% | $155.51M | 0.35% |
| IWN | 48.41% | $11.18B | 0.24% |
| ISCG | 48.25% | $696.78M | 0.06% |
| FYX | 48.15% | $845.65M | 0.6% |
| NUSC | 48.12% | $1.17B | 0.31% |
| ARKG | 48.06% | $1.10B | 0.75% |
| PTH | 47.91% | $97.64M | 0.6% |
| GSSC | 47.82% | $597.16M | 0.2% |
| SMMD | 47.78% | $1.51B | 0.15% |
